related documents
- ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL) Conferences
- OPTIMAL DURATION OF ANTICOAGULANT THERAPY FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS Conferences